Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMOFlipid in Patients Intolerant to Intralipid
NCT03054948Phase 4Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of SMOFlipid in short bowel syndrome (SBS) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Aspartate Aminotransferase, Blood Glucose and 4 more. Planned start Feb 2017; status: withdrawn.
02
Drugs
SMOFlipid
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03054948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054948.